Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants-Reference-Cited by-同舟云学术

Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants

Published:2022-07-01 Issue:7 Volume:7 Page:747
ISSN:2380-6583
Container-title:JAMA Cardiology
language:en
Short-container-title:JAMA Cardiol

Author:

Bikdeli Behnood¹²³⁴,Zahedi Tajrishi Farbod⁵,Sadeghipour Parham⁶⁷,Talasaz Azita H.⁸⁹,Fanikos John¹⁰,Lippi Giuseppe¹¹,Siegal Deborah M.¹²,Eikelboom John W.¹³,Monreal Manuel¹⁴,Jimenez David¹⁵,Connors Jean M.¹⁶,Ageno Walter¹⁷,Barnes Geoffrey D.¹⁸,Piazza Gregory¹²,Angiolillo Dominick J.¹⁹,Parikh Sahil A.⁴²⁰,Kirtane Ajay J.⁴²⁰,Lopes Renato D.²¹²²,Bhatt Deepak L.¹,Weitz Jeffrey I.²³²⁴,Mehran Roxana²⁵,Krumholz Harlan M.³²⁶²⁷,Goldhaber Samuel Z.¹²,Lip Gregory Y. H.²⁸²⁹

Affiliation:

1. Cardiovascular Medicine Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts

2. Thrombosis Research Group, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts

3. Yale New Haven Hospital/Yale Center for Outcomes Research and Evaluation, New Haven, Connecticut

4. Cardiovascular Research Foundation, New York, New York

5. Cardiac Primary Prevention Research Center, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran

6. Cardiovascular Intervention Research Center, Rajaie Cardiovascular, Medical, and Research Center, Iran University of Medical Sciences, Tehran, Iran

7. Clinical Trial Center, Rajaie Cardiovascular, Medical, and Research Center, Iran University of Medical Sciences, Tehran, Iran

8. Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran

9. Virginia Commonwealth University, Richmond

10. Department of Pharmacy, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts

11. Section of Clinical Biochemistry, University of Verona, Verona, Italy

12. Division of Hematology, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada

13. Population Health Research Institute, Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada

14. Department of Internal Medicine, Hospital Universitari Germans Trials i Pujol, Universidad Católica San Antonio de Murcia, Barcelona, Spain

15. Respiratory Department, Hospital Ramón y Cajal and Medicine Department, Universidad de Alcalá (Instituto de Ramón y Cajal de Investigación Sanitaria), Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Madrid, Spain

16. Hematology Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts

17. Department of Medicine and Surgery, University of Insubria, Varese, Italy

18. Frankel Cardiovascular Center, Department of Internal Medicine, University of Michigan, Ann Arbor

19. Division of Cardiology, University of Florida College of Medicine, Jacksonville, Florida

20. Division of Cardiology, New York-Presbyterian Hospital/Columbia University Irving Medical Center, New York

21. Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina

22. Brazilian Clinical Research Institute, São Paulo, Brazil

23. McMaster University, Hamilton, Ontario, Canada

24. Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada

25. Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York

26. Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut

27. Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut

28. Liverpool Centre for Cardiovascular Science, Liverpool Heart and Chest Hospital, University of Liverpool, Liverpool, United Kingdom

29. Department of Clinical Medicine, Aalborg University, Aalborg, Denmark

Publisher

American Medical Association (AMA)

Subject

Cardiology and Cardiovascular Medicine

Link

https://jamanetwork.com/journals/jamacardiology/articlepdf/2793119/jamacardiology_bikdeli_2022_rv_220002_1656698790.00688.pdf

Reference95 articles.

1. Dabigatran versus warfarin in the treatment of acute venous thromboembolism.;Schulman;N Engl J Med,2009

2. Oral apixaban for the treatment of acute venous thromboembolism.;Agnelli;N Engl J Med,2013

3. Oral rivaroxaban for symptomatic venous thromboembolism.;Bauersachs;N Engl J Med,2010

4. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.;Büller;N Engl J Med,2012

5. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.;Büller;N Engl J Med,2013

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The use of reduced DOAC doses in atrial fibrillation patients does not always lead to good anticoagulation levels and avoid adverse events;International Journal of Cardiology;2024-12

2. Anticoagulant therapy in renal insufficiency theme: Anticoagulation in complex situations;Thrombosis Research;2024-09

3. Hemodynamics Affects Factor XI/XII Anticoagulation Efficacy in Patient-Specific Left Atrial Models;2024-08-28

4. Direct-Acting Oral Anticoagulants and Antiseizure Medications for Atrial Fibrillation and Epilepsy and Risk of Thromboembolic Events;JAMA Neurology;2024-08-01

5. Rivaroxaban Versus Apixaban: A Comparison Without a Simple Solution;Mayo Clinic Proceedings: Innovations, Quality & Outcomes;2024-08